PepGen Inc. (PEPG)
Health Care · Oligonucleotide therapeutics · Nasdaq
Clinical-stage biotech developing next-generation oligonucleotide therapies using cell-penetrating peptides to treat severe neuromuscular and neurological diseases.
What PepGen Inc. does
PepGen Inc. is a clinical-stage biotechnology company developing advanced oligonucleotide therapies for severe neuromuscular and neurological diseases. The company has developed a proprietary Enhanced Delivery Oligonucleotide (EDO) platform that leverages cell-penetrating peptides (CPPs) to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its lead candidate, PGN-EDODM1, is in clinical development for the treatment of myotonic dystrophy type 1 (DM1), with Phase 1 and Phase 2 trials underway across multiple geographies.
Themes: ["Oligonucleotide therapies","Rare genetic neuromuscular diseases","Myotonic dystrophy","Clinical-stage biotechnology","Drug delivery optimization"]
Fundamentals
- Price$2.34 as of 2026-07-10 close
- Market cap$162M as of 2026-07-13
- 1-year return+87.2% as of 2026-07-10 close
- ROE-59.9% as of 2026-07-13
- Debt / equity0.00 as of 2026-07-13
- Beta1.85 as of 2026-07-13
Key risks (from latest filing)
["PGN-EDODM1 Phase 2 study remains on partial clinical hold in the U.S. pending FDA resolution of safety/efficacy questions, creating regulatory and development timeline uncertainty.","As a clinical-stage company with no approved products, PepGen has no revenue and requires substantial capital to fund ongoing clinical trials and future development, with significant financing risk if capital markets close or funding becomes unavailable.","Success depends on demonstrating sufficient efficacy and safety of PGN-EDODM1 in Phase 2 trials; failure to meet primary endpoints or unexpected adverse events could halt development and eliminate the company's primary asset."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.